The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

A building construction product comprising an ionochromic dye, wherein the building construction product has a first color when the product comprises water, wherein the first color is dependent on the presence of metal ions in solution in the product; and wherein the product has a second color when the product has solidified. Methods of monitoring setting and drying reactions of building construction products, including setting-type and drying-type joint compounds and plasters.

A building construction product comprising an ionochromic dye, wherein the building construction product has a first color when the product comprises water, wherein the first color is dependent on the presence of metal ions in solution in the product; and wherein the product has a second color when the product has solidified. Methods of monitoring setting and drying reactions of building construction products, including setting-type and drying-type joint compounds and plasters.

A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt, is disclosed. Compositions comprising the compound and methods of use are also disclosed. Those dimeric Evans Blue derivatives, denoted as N(tEB)2, reversibly bind two molecules of albumin via the two albumin binding regions of each NtEB in the dimer, resulting in significantly increased binding affinity to albumin and extended circulation half-life in vivo. Further, when the N(tEB)2 is conjugated to a peptide therapeutic, the in situ formation of the complex of N(tEB)2 with two albumin molecules resulted in increased resistance of the peptide therapeutic from proteolysis.

##STR00001## ##STR00002## ##STR00003## ##STR00004##

A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt, is disclosed. Compositions comprising the compound and methods of use are also disclosed. Those dimeric Evans Blue derivatives, denoted as N(tEB)2, reversibly bind two molecules of albumin via the two albumin binding regions of each NtEB in the dimer, resulting in significantly increased binding affinity to albumin and extended circulation half-life in vivo. Further, when the N(tEB)2 is conjugated to a peptide therapeutic, the in situ formation of the complex of N(tEB)2 with two albumin molecules resulted in increased resistance of the peptide therapeutic from proteolysis.

##STR00001## ##STR00002## ##STR00003## ##STR00004##

A head-up display apparatus includes: a display unit configured to output projection light; at least one reflector configured to reflect the projection light; a housing, which has an opening portion, and is configured to store the display unit and the reflector therein; a cover member configured to cover the opening portion; and a polarizing plate with a retardation layer, which is arranged on a housing inner side of the cover member, and includes a retardation layer and a polarizer in the stated order from a cover member side. The retardation layer has an in-plane retardation Re(550) of from 100 nm to 200 nm. The head-up display apparatus is configured so that an angle of reflection of the projection light output from the housing through the opening portion with respect to a windshield is 30° or less, or is 40° or more.

A head-up display apparatus includes: a display unit configured to output projection light; at least one reflector configured to reflect the projection light; a housing, which has an opening portion, and is configured to store the display unit and the reflector therein; a cover member configured to cover the opening portion; and a polarizing plate with a retardation layer, which is arranged on a housing inner side of the cover member, and includes a retardation layer and a polarizer in the stated order from a cover member side. The retardation layer has an in-plane retardation Re(550) of from 100 nm to 200 nm. The head-up display apparatus is configured so that an angle of reflection of the projection light output from the housing through the opening portion with respect to a windshield is 30° or less, or is 40° or more.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.